Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease

A double-blind, placebo-controlled trial of 2-dimethylaminoethanol was undertaken in 27 patients with moderately severe or severe Alzheimer's disease. Of 13 patients in the drug group, 6 were withdrawn in the first 5 weeks of the trial because of side effects, which included drowsiness and reta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of psychiatry 1981-07, Vol.138 (7), p.970-972
Hauptverfasser:	Fisman, M, Mersky, H, Helmes, E
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alzheimer Disease - drug therapy Clinical Trials as Topic Confusion - chemically induced Deanol - adverse effects Deanol - therapeutic use Dementia - drug therapy Double-Blind Method Ethanolamines - therapeutic use Female Humans Hypertension - chemically induced Male Placebos Psychomotor Disorders - chemically induced Sleep Stages Sleep Wake Disorders - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A double-blind, placebo-controlled trial of 2-dimethylaminoethanol was undertaken in 27 patients with moderately severe or severe Alzheimer's disease. Of 13 patients in the drug group, 6 were withdrawn in the first 5 weeks of the trial because of side effects, which included drowsiness and retardation, with an increase of confusion and mild elevation of blood pressure. No significant benefit appeared from the drug treatment.
ISSN:	0002-953X 1535-7228
DOI:	10.1176/ajp.138.7.970